AMGN — Amgen Inc.

Is AMGN overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Drug Manufacturers - General

Overbought As of November 17, 2026

Amgen Inc. (AMGN) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Drug Manufacturers - General) last closed at $457.93. The rating moved from Neutral to Overbought on November 16, 2026.

See all overbought Healthcare stocks →

AI analysis

Amgen Inc. (AMGN) combines stable cash flows from established biologic franchises with a pipeline and balance-sheet flexibility that support near-term downside protection and medium-term upside through new indications and M&A. Sector flows favoring large-cap pharma and durable specialty distribution channels provide additional technical and demand support. Key negatives include biosimilar erosion, pricing/reimbursement pressure and the usual clinical/regulatory binary risks for pipeline assets. Overall outlook is for modest appreciation over the next month if market sentiment stays constructive and no major clinical or regulatory setbacks occur.

Key factors

  • Large-cap, diversified biopharma franchise with steady, predictable revenue from established biologics and recurring specialty medicines
  • Strong balance sheet and cash generation supporting dividends, buybacks and M&A optionality
  • Sector flows favoring defensive, large-cap pharma names amid risk-on but consolidating market, providing relative bid support
  • Pipeline and late-stage assets provide upside through new indications and lifecycle management for core brands
  • Distribution and specialty pharmacy trends (shift to specialty care and infusion) could sustain demand for injectable biologics
  • M&A and consolidation trends in large-cap pharma increase the probability of targeted acquisitions to bolster specialty franchises

Risks

  • Biosimilar and generic competition to key biologics compressing revenues and margins over time
  • Pricing pressure and reimbursement headwinds driven by payors, and potential downstream impacts from Medicare Advantage program integrity enforcement
  • Clinical or regulatory setbacks for pipeline candidates that would reduce future revenue growth visibility
  • Supply-chain or manufacturing disruptions affecting biologics production and shipment
  • Increased competition from emerging modalities (e.g., novel obesity/GLP‑1-like therapies that change market dynamics for related indications) and competitor launches
  • Macro volatility or sudden risk-off flows that reduce defensive-sector bid and hurt valuation multiples

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for AMGN — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.